


## PHARMACEUTICAL 2017



## Carisma Therapeutics Inc. Rank 5 of 292





## PHARMACEUTICAL 2017



## Carisma Therapeutics Inc. Rank 5 of 292



The relative strengths and weaknesses of Carisma Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Carisma Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Carisma Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 322%, being 319% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	25,927
Cost of Goods Sold	0
Intangible Assets	16,864
Liabilities, Current	3,980
Liabilities, Non-Current	0
Other Assets	60,510
Other Compr. Net Income	0
Other Expenses	-1,095
Other Liabilities	0
Other Net Income	28,605
Other Revenues	406
Property and Equipment	796
Research and Development	13,479
Selling, General and Administrative Expense	14,736

Output Variable	Value in 1000 USD
Assets	104,097
Liabilities	3,980
Expenses	27,120
Revenues	406
Stockholders Equity	100,117
Net Income	1,891
Comprehensive Net Income	1,891
Economic Capital Ratio	322%

